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Abstract
Background: Human parvovirus B19 (B19V) is a frequent contaminant of blood and plasma-derived medicinal
products. Three distinct genotypes of B19V have been identified. The distribution of the three B19V genotypes has
been investigated in various regions or countries. However, in China, data on the existence of different B19V
genotypes are limited.
Methods: One hundred and eighteen B19V-DNA positive source plasma pool samples collected from three Chinese
blood products manufacturers were analyzed. The subgenomic NS1/VP1u region junction of B19V was amplified by
nested PCR. These amplified products were then cloned and subsequently sequenced. For genotyping, their
phylogenetic inferences were constructed based on the NS1/VP1-unique region. Then putative recombination
events were analyzed and identified.
Results: Phylogenetic analysis of 118 B19V sequences attributed 61.86 % to genotype 1a, 10.17 % to genotype 1b,
and 17.80 % to genotype 3b. All the genotype 3b sequences obtained in this study grouped as a specific, closely
related cluster with B19V strain D91.1. Four 1a/3b recombinants and 5 new atypical B19V variants with no
recombination events were identified.
Conclusions: There were at least 3 subtypes (1a, 1b and 3b) of B19V circulating in China. Furthermore, putative
B19V 1a/3b recombinants and unclassified strains were identified as well. Such recombinant and unclassified strains
may contribute to the genetic diversity of B19V and consequently complicate the B19V infection diagnosis and NAT
screening. Further studies will be required to elucidate the biological significance of the recombinant and
unclassified strains.
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Background
Human parvovirus B19 (B19V), member of the Erythro-
parvovirus genus within the Parvoviridae family, is a
widespread human pathogen that be associated with a
broad range of clinical manifestations [1–4]. Infection of
B19V in the normal population is usually asymptomatic
or a self-limiting febrile illness, but can sometimes be
life-threatening in high-risk populations, such as transi-
ent aplastic crisis (TAC) in patients with haematological
disorders, chronic anemia in immunodeficient patients
and abortion or hydrops fetalis in pregnant women.
B19V is a frequent contaminant of blood and plasma-
derived medicinal products (PDMPs) [5–9]. Many
reports documented the transmission of B19V infection
by the administration of contaminated PDMPs, such as
clotting factor concentrates, intravenous immunoglobu-
lin (IVIG), intramuscular immunoglobulin (IMIG), and
albumin, manufactured from a large number of plasma
donations [10–13]. In order to ensure the quality and
safety of PDMPs, since 2004, European Pharmacopoeia
proposes NAT (nucleic acid testing) for B19V as an
in-process test and stipulates a limit of 104 IU/ml for
manufacturing pools used for the manufacture of anti-D
immunoglobulin and virus-inactivated pooled plasma
[14]. U.S. FDA and the Plasma Protein Therapeutics
Association (PPTA) recommended the same limit for
levels of B19V in plasma pools destined for making all
kinds of PDMPs in B19V NAT testing [15, 16]. One
study demonstrated that, minipool NAT screening for
B19V could effectively lower the prevalence and level of
B19V in the final products and in the majority of cases
render it undetectable and hence potentially reduce the
risk of B19V transmission [17].
The genome of B19V consists of a single strand of
linear DNA, about 5,600 nucleotides, which encodes a
single nonstructural protein (NS1), multiple functional
protein essential to viral replication and regulation of
gene expression that is cytotoxic to host cells, and two
structural proteins viral protein 1 (VP1) and viral protein
2 (VP2) [18, 19]. In addition, B19V also encodes two
other smaller nonstructural proteins, 7.5 kDa and
11 kDa. The 11 kDa protein has been shown to have a
role in virion production and trafficking in infected cells
and also contributes to erythroid progenitor cell death
during B19V infection, whereas the 7.5 kDa protein has
not yet been reported to have functions during B19V
infection [20, 21].
B19V is now formally subdivided into three distinct
genotypes (1, 2, 3), which were defined as having
approximately 10 % divergence in overall DNA sequence
[22]. Furthermore, phylogenetic analyses have revealed
two subgroups within genotypes 1 and 3 [23, 24]. Genotype
1 is represented by the prototype strain Au (GenBank
Accession Number M13178) and Vn147 (GenBank
Accession Number DQ357064), as the prototype strain for
genotype 1a and 1b respectively. A recent study showed
that two groups of genotype 1a co-existed globally, and
that they were different in genome-wide synonymous
positions. Thus it was proposed that the two groups of
genotype 1a should be called subtype 1a1 and 1a2, respect-
ively [25]. Genotype 2 is represented by the prototype
strain A6 (GenBank Accession Number AY064475) and
Lali (GenBank Accession Number AY044266). Genotype 3
is represented by V9 (GenBank Accession Number
AX003421) and D91.1 (GenBank Accession Numbers
AY083234), as the prototype strain for genotype 3a and 3b,
respectively. All B19V genotypes appear to circulate but
their relative frequency is strikingly different and their
spatial and temporal distribution is not uniform [26].
Despite the variations among the genomes, these three
B19V genotypes are assumed to have similar biological
properties, pathogenic capacities, and transmission routes
and pose a similar diagnostic challenge in the clinical
setting [27, 28]. Nevertheless, recent reports presented evi-
dence that genotype 2-specific sequences predominantly
associated with heart tissue disease proposing that patho-
genic properties might differ according to the genotype
[29, 30]. Since all genotype variants of B19V can be
contaminants of blood and PDMPs, the NAT assay as an
in-process test used in the manufacturing of PDMPs must
be able to detect all genotype variants. As genetic variation
was to be expected in the future, the importance of depos-
iting DNA sequence for B19V strains in the databases was
emphasized in order to ensure that as much information is
available, a good assay design as be enabled [31].
We previously did research on the prevalence of B19V
in Chinese plasma pools [32]. Here, we identified the
B19V genotypes in B19V-DNA positive plasma pool sam-
ples and reported the diversity of these B19V sequences.
Methods
Samples
A total of 118 B19V-DNA positive source plasma pool
samples from three Chinese blood products manufac-
turers (A, B, and C) were included in the present study.
These samples were confirmed positive for B19V DNA
by an in-house qPCR assay adapted for all three geno-
types of B19V [32]. Manufacturer A, B and C are located
in central China, northern China and southwestern
China, respectively. The plasma samples were collected
between 2008 and 2013 (Table 1). Each batch of the
plasma pools from the three manufacturers consisted of
2000 to over 8300 donations. Each donation mixed in
the plasma pools was tested negative for anti-human im-
munodeficiency virus type 1/2 antibody (anti-HIV 1/2),
hepatitis B surface antigen (HBsAg) and anti-hepatitis C
virus antibody (anti-HCV) by ELISA, before pooling.
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DNA extraction and nested-PCR
DNA extraction from the source plasma pool samples
was performed with the High Pure Viral Nucleic Acid
Kit (Roche Diagnostics, Mannheim, Germany) according
to the manufacturer’s instructions. Viral DNA for
sequencing was prepared by nested-PCR amplification of
a 1,100-bp region spanning the NS1-VP1u junction with
the primers previously described by Servant et al. [22].
The PCR products were analyzed by electrophoresis in
1 % agarose gels and subsequently purified by using a
TIANgel Midi Purification Kit (Tiangen Biotech, Beijing,
China). Purified amplicons were cloned into the
pMD18-T vector (TaKaRa Bio, Dalian, China) and a
single clone derived from the PCR product of each
sample was sequenced. As for samples suspected of
recombination, over 20 additional clones derived from
each sample were cloned and sequenced.
Sequencing and phylogenetic analyses
The NS1/VP1-unique region of B19V positive samples
were sequenced and included in the following phylogen-
etic analyses. Sequencing was carried out by the dideox-
ynucleotide chain termination method on an ABI
3730XL DNA Analyzer with BigDye® Terminator v3.1
Cycle Sequencing Kit in accordance with the manufac-
turer’s instructions (Applied Biosystems, Foster City,
USA). Multiple sequence alignment was carried out
through Clustal W. The reliability of the alignment was
additionally checked by using the BioEdit program
(Department of Microbiology, North Carolina State
University, Raleigh, NC, USA; http://www.mbio.ncsu.
edu/BioEdit/bioedit.html). The B19V genotypes were de-
termined by phylogenetic tree analysis using MEGA
version 6.0 and the 1069 nt NS1/VP1-unique region
junction (positions 1884 to 2952 in M13178) proposed
for genotyping [22]. One hundred and ninety-four non-
redundant sequences spanning this region were down-
loaded from GenBank (December 2015) and included in
the analysis. Genetic distances were calculated using the
Kimura two-parameter method and phylogenetic trees
were constructed by the neighbour-joining method. The
reliability of clusters was evaluated using interior branch
test with 1000 replicates. The sequences that were
strongly positioned inside one of the genotype reference
groups were compiled and their respective genotypes
were assigned.
Recombination analysis
The sequences suggestive of recombination by the above
phylogenetic inferences that presented unclear clustering
were subjected to recombination analysis, as described
previously [33]. For this analysis, the bootscanning
method implemented in SimPlot v.3.5.1 for Windows
was used with the following parameters: window size
250 bp, step size 20 bp, F84 model of evolution (max-
imum likelihood) as the model to estimate nucleotide
substitution, transition/transversion ratio of 2.0, and a
bootstrap of 100 trees [33–35]. The significance thresh-
old for the bootscan was set at 70 %. The positions of
crossover sites were defined on the basis of the distribu-
tion of informative sites supporting the two incongruent
topologies that maximized the chi-square value, a
method implemented in SimPlot. Trees were displayed
using MEGA version 6.0 software [36].
Nucleotide sequence accession numbers
The GenBank accession numbers for the NS1-VP1u
region of B19V reported in this study are KR819768-
KR819885.
Results
Sequencing and phylogenetic analysis of sequences
Sequencing and subsequent phylogenetic analysis were
performed on a 1069-bp fragment (positions 1884 to
2952 in M13178) spanning part of the NS1 and VP1
gene of the B19V genome to determine the B19V
genotype (Fig. 1). One hundred and eighteen sequences
were obtained in this study, and designated according to
its origin, for instance, A16 represented the B19V
sequence amplified from the 16th sample from manufac-
turer A. Phylogenetic analysis of 118 sequences obtained
in this study, together with 194 sequences retrieved from
GenBank (December 2015), revealed the presence of
B19V genotype 1 [91 of 118 (77.12 %)] and genotype 3







No. of samples with genotypes: Mean genetic




A (Central China) 89 2008–2013 60 6 13 5 5 3.79
B (Northern China) 8 2008 0 0 7 1 0 0.45
C(South-western China) 21 2008 13 6 1 1 0 2.78
Total 118 2008–2013 73 12 21 7b 5 4.27
aDistance between all sequences from the same location
bFour of these recombinants were identified to be natural, while the others were supposed to be amplification artefacts
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[27 of 118 (22.88 %)]. None of the samples clustered
with the reference genotype 2 sequences (Fig. 1a).
As indicated in the phylogenetic tree, altogether 255
sequences belonging to genotype 1, including the 91
new sequences described here, with the mean genetic
distance of 1.21 % and a maximal genetic distance of
5.60 % (KC013338 and A49, FW377125). Among the
genotype 1 sequences, seventy-three new sequences
together with 161 reference sequences clustered together
to form the genotype 1a group, with the mean genetic
distance of 0.89 % and a maximal genetic distance of
2.79 % (A45 and DQ293995, KC013321). Twelve new
sequences together with two reference sequences clus-
tered together to form the genotype 1b group, with the
mean genetic distance of 1.11 % and a maximal genetic
distance of 2.97 % (C33 and DQ357064). One new
sequence (A128) displayed between the monophyletic
clusters of genotype 1a and genotype 1b, suggesting the
recombination between genotype 1a and 1b. Additionally,
five new sequences (A70, A72, A22, A27 and A49) and
one reference sequence (FW377125) from GenBank
seemed to represent the outliers of genotype 1 (Fig. 1a).
Not a single genotype 2 virus was found in this study.
Fourteen reference sequences from the GenBank formed
the genotype 2 group, with the mean genetic distance of
1.66 % and a maximal genetic distance of 4.47 %
(DQ333427 and AY064476).
The 53 sequences belonging to genotype 3, including
the 27 new sequences described here, with the mean
genetic distance of 1.94 % and a maximal genetic
Fig. 1 a Phylogenetic tree based on 312 sequences (118 obtained in this study and 194 retrieved from GenBank). b Phylogenetic tree based on
21 B19V-genotype 3 sequences from this study and a set of sequences downloaded from GenBank used as references for the different genotypes.
Phylogenetic analyses are based on a region of 1069 nt and the neighbor-joining algorithm using the Kimura two-parameter model. The
reference sequences are shown without symbols and are labeled with their GenBank accession number and isolate name. Sequences are from
three Chinese blood products manufacturers: Manufacture A (black circles); Manufacture B (black squares); and Manufacture C (black triangles).
Bootstrap replication frequencies ≥50 % are indicated above nodes. The basis of each isosceles triangle is proportional to the number of
sequences. Branch lengths are drawn to scale
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distance of 7.88 % (A71 and NC_004295). Six new
sequences (A71, A74, B3, C29, A32 and A58) failed to
group within the clusters of genotype 3a or 3b; they
were suspected outliers or recombinants and were
discussed later (Fig. 1a). With the exception of the
outliers, all sequences fell into two groups (designated as
genotype 3a and 3b, respectively). The mean intra-group
distances were 0.95 and 1.16 %, respectively. Within
genotype 3b, three main clusters were observed and all
21 new-found sequences fell into the single cluster
(cluster 3). Moreover, seven of our 8 sequences from
manufacture B belonged to this cluster (Fig. 1b).
Recombination analysis of the unclassified sequences
A total of 12 new sequences could not be clearly
assigned to a subgenotype by phylogenetic analysis
described above. These sequences displayed distinct
from the reference sequences from GenBank, implying
they might be new subgroups or second-generation
recombinants. These sequences were subjected to
recombination analysis.
Further analysis using SimPlot and bootscanning of the
amplified fragment (1069-bp; positions 1884 to 2952 in
M13178) indicated recombinant events between different
genotypes. The breakpoints were further examined by
constructing phylogenetic trees of the 2 nonrecombinant
segments (Fig. 2 and Additional file 1: Figure S1).
Among the outliers of genotype 1, two sequences were
identified to be the recombinants. A70 showed two
recombinant events between genotype 1a (between nt
1884 and 2515), genotype 3b (between nt 2533 and
2620) and genotype 1a (between nt 2646 and 2952)
(Fig. 2a). A72 showed two recombinant events between
genotype 1a (between nt 1884 and 2531), genotype 3b
(between nt 2600 and 2692) and genotype 1a (between
nt 2744 and 2952) (Additional file 1: Figure S1a). In
contrast, no recombinant signals were detected in the 4
remaining samples (A128, A22, A27 and A49) (explora-
tory tree analysis not shown), thus they were supposed
to be putative new subtypes of genotype 1.
With regard to the outliers in genotype 3, three
sequences were identified to be genotype 1a/3b recombi-
nants. A71 showed a single recombinant event between
genotype 1a (between nt 1884 and 2367) and genotype
3b (between nt 2397 and 2952) (Fig. 2b). B3 showed a
single recombinant event between genotype 1a (between
nt 1884 and 2199) and genotype 3b (between nt 2242
and 2952) (Fig. 2c). C29 showed a single recombinant
event between genotype 1a (between nt 1884 and 2163)
and genotype 3b (between nt 2190 and 2952) (Fig. 2d).
Besides, the putative recombination signals were also
detected in sequences A32 and A58 (Additional file 1:
Figure S1b–c). A32 showed a single recombinant event
between genotype 1a (between nt 1884 and 2068) and
genotype 3b (between nt 2169 and 2952) (Additional file 1:
Figure S1b). A58 showed a single recombinant event
between genotype 3b (between nt 1884 and 2638) and
genotype 1a (between nt 2744 and 2952) (Additional file 1:
Figure S1c). However, as the breakpoints of these 2
sequences located either on the 5′ or 3′ end of each
sequence, further analysis of longer sequences will be
required to be demonstrative. In contrast, sequence A74
did not show any putative recombination signals, thus it
was supposed to be putative new subtype of genotype 3.
Further identification of the putative recombinants
A single plasma pool sample representing a mixture of
thousands of plasma samples might easily contain B19V
from different individuals and possibly of different geno-
types. Thus, it was possible that the apparent recombi-
nants described were in fact amplification artefacts if
B19V of multiple origins coexisted in a sample. In order
to explore if these recombinants are natural or not, we
sequenced and analyzed more than 20 additional clones
derived from the samples suspected of recombination
(A32, A58, A70, A71, A72, B3 and C29). The genotypes of
all these additional clones were listed in Additional file 2:
Table S1.
For sample A70 and A71, all the additional clones
derived from these 2 samples were identified as subtype
1a, while for sample B3, all were identified as subtype
3b. Furthermore, these 3 samples presented clones of
the same genotype with nearly identical sequences,
differences being related either to true quasispecies situ-
ation or to small errors during amplification. Although
coexistence of subtype 1a and 1b have been identified in
sample C29, none of the additional clones derived from
this sample belonged to subtype 3b. As no coexistence
of subtype 1a and 3b was found in each of the 4 samples
described above, the artificial recombination of subtype
1a and 3b can hardly happen in these samples. Thus,
B19V 1a/3b recombinants derived from these 4 samples
in our study were supposed to be the natural recombi-
nants rather than the laboratory artefacts.
As for the samples A32, A58 and A72, coexistence of
subtype 1a and 3b and additional 1a/3b recombinants
were identified in the additional clones. Sample A32 was
a mixture of dominant subtype 1a (15 clones, with
percent identity ranging from 96.7 to 100 %) and a
minority of subtype 3b (2 clones, with 99.0 % sequence
identity) and 3 different additional clones corresponding
to be apparent recombinants. Sample A58 was a mixture
of dominant subtype 3b (12 clones, with percent identity
ranging from 98.1 to 100 %) and a minority of subtype
1a (9 clones, with percent identity ranging from 98.7 to
100 %) and 1 additional clone corresponding to be
apparent recombinant. Sample A72 was a mixture of
dominant subtype 1a (16 clones, with percent identity
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Fig. 2 Analyses of four B19V 1a/3b recombinant sequences. Panel a, b, c and d represented the results of sequence A70, A71, B3 and C29,
respectively. The left part of each panel was the results of bootscan analysis. At the right part of each panel were the neighbour-joining trees
established on the basis of the fragments between breakpoints, as indicated by a bootscan plot of the sequence
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ranging from 96.4 to 100 %) and a minority of subtype
3b (3 clones, with percent identity ranging from 99.3 to
99.7 %) and 3 different additional clones corresponding
to be apparent recombinants. These 6 additional
suspected recombinant sequences described above, were
different from original recombinant sequences derived
from the same sample. In order to explore the possibility
of amplification artefact occurred in samples A32, A58
and A72, the similarity and identity among the nucleo-
tide sequences of the genotype 1a and 3b fragment
involved in the recombinant event as defined by
bootscanning and the non-recombinant genotype 1a and
3b fragment from the same plasma sample was investi-
gated respectively. Results showed that in sample A32,
nucleotide sequences of the subtype 1a and 3b fragment
of the original recombinant sequence A32 and additional
recombinant sequence A32_c1 were identical to that of
non-recombinant subtype 1a and 3b fragment from the
same plasma sample. Thus, the sequences A32 and
A32_c1 were likely to be artificial recombinants between
B19V subtype 1a and 3b strains coexistence in the
sample A32. There were same scenarios for sequences
A58, A72, A72_c3 and A72_c5. On the contrary,
sequences A32_c19, A32_c20 and A58_c1 were sup-
posed to be the natural recombinants.
In conclusion, four sequences (A70, A71, B3, and C29)
were more likely to be bona fide recombinants. The
other 3 samples (A32, A58 and A72) were containing
multiple B19V strains originating from different samples
in the plasma pool, thus the recombinants derived from
these 3 samples were likely to be amplification artefacts.
Discussion
Accumulating evidences have confirmed that the preva-
lence of each genotype varies in relation to geographic
origin, population and sample type. Genotype 1, espe-
cially subtype 1a, is the most prevalent B19V currently
circulating in most parts of the world and is represented
by the prototype strain Au (GenBank Accession Number
M13178) [37]. Genotype 2 is a rarely occurring genotype
and has been sporadically found circulating in several
European countries, Brazil and the United States with
lower frequency and is represented by the prototype
strain A6 (GenBank Accession Number AY064475) and
Lali (GenBank Accession Number AY044266) [38–42].
Genotype 3 seems to be endemic to Ghana, but has also
been found in Brazil, France, North India and the United
States [22, 43–46]. Genotype 3 is represented by V9
(GenBank Accession Number AX003421) and D91.1
(GenBank Accession Number AY083234), as the proto-
type strain for genotype 3a and 3b respectively.
There is paucity of data on B19V genotypes circulating
in China. Published data were limited to Ke’s study, in
which the fragments approximately 1200 bp from NS1-
VP1u region of five B19V-DNA positive blood donation
samples were sequenced and these sequences were iden-
tified to be B19V genotype 1a by phylogenetic analysis
[47]. In this study, we genotyped the B19V sequences in
118 B19V-DNA positive plasma pool samples. Using
phylogenetic analysis, we demonstrated that at least
three B19V subtypes, 1a, 1b and 3b, were currently
present in China. In agreement with previous studies,
our results indicated significantly well-defined subtypes
within genotypes 1 and 3 [23, 48, 49]. Although the
primers and probe used in this study were capable of
detecting B19V genotype 2, no genotype 2 was detected.
Absence of genotype 2 in this study was as expected,
since this genotype was found relatively infrequently
throughout the world. Alternatively, it is possible that
mixtures of genotype 2 and other genotypes were
present in the same sample, however, the identification
might be compromised if the genotype 2 viral variants
were present at a lower load or genotype 2 strains
escaped detection because just one clone of each sample
was sequenced and analyzed in this study, as discussed
later in the limitations. Additionally, it is also possible
that this was a result of limited sampling in restricted
area.
In this study, phylogenetic analysis indicated B19V
genotype 1 was predominant, with 91 of 118 B19V
sequences (77.12 %) belonging to genotype 1. These
results were in accordance with data collected from
Vietnam, India, and Korea, suggesting the predominance
of genotype 1 in Asia, and further confirming the pre-
dominance of genotype 1 in most parts of the world [24,
45]. Our study also presented the first report of B19V
genotype 3 circulating in Chinese plasma donations. We
identified 27 B19V genotype 3 sequences. Interestingly,
all these new sequences except six outliers were
subtyped as 3b and fell into the single cluster (genotype
3b cluster 3), most similar to strain D91.1 (AY083234)
isolated in France. Moreover, seven of our 8 sequences
from manufacture B belonged to this cluster. This
suggested B19V subtype 3b might be endemic in certain
regions of China. These observations might also suggest
geographic differences in the spread of different B19V
genotypes in diverse parts of China. However, these indi-
cations are based on relatively small numbers of samples
collected in restricted area. Therefore, the data obtained
in this study does at least partly reflect the status of
B19V spreading in China.
The mutation rates of B19V are high for a DNA virus
and comparable to those of RNA viruses [50, 51]. In
accordance with a previous report, within the 1069-nt
region, genotype 3 is the most diverse in this study, with
a mean intragenotype distance of 1.94 %, followed by
genotypes 2 (1.66 %) and 1 (0.89 % and 1.11 % for 1a
and 1b respectively) [37]. They indicated that genotype 3
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had a longer evolutionary history than the other two
genotypes and that genotype 1 may be of a more recent
origin [50]. Interestingly, the results of phylogenetic
analysis indicated that genotype 3b sequences from
China grouped as a specific, closely related cluster with
B19V strain D91.1. Moreover, the further alignment and
analysis showed that the genotype 3b sequences in this
cluster were closely related to each other, with a genetic
distance less than 1.61 %. These observations might
suggest that B19V genotype 3b were introduced recently
into China.
Besides the well-defined genotypes, the present study
also suggested the circulation of B19V recombinants and
few unclassified strains in China. We identified 7 puta-
tive B19V genotype 1a/3b recombinant viruses initially
and further analyses indicated that 4 of these recombi-
nants were natural while the other 3 were likely to be
amplification artefacts. Two of these 4 natural recombi-
nants (A70 and A71) were collected from manufacturer
A located in central China where at least two different
viral genotypes co-circulate, in accordance with the
hypothesis that recombination of intra- and inter-B19V
genotypes occurs in regions where different viral genotypes
co-circulate [33]. Finding of these recombinants in our
study was not surprising, as the frequent recombination in
the parvoviruses and the frequent co-infection of more
than one B19V strains, in some case co-infection of two dif-
ferent genotypes, allowing for the possibility of recombin-
ation [52–54]. A previous study by da Costa and colleagues
has described the occurrence of 1a/3b recombinant in a
single host and the recombination site located in the NS1
gene of B19V [33]. In a very recent publication, Shen et al.
has analyzed 100 available NS1 and VPs genes of B19V
from GenBank and found the recombination events
between B19V genotype 1 and 2 as well as between geno-
type 1 and 3, leading to the recombinant cluster genotype
2, from which the recombinant breakpoints were found in
NS1 or VPs of B19V [55]. In our study, B19V genotype 1a/
3b recombinant viruses were identified, in accordance with
da Costa’s and Shen’s reports. However, we did not detect
the existence of B19V genotype 2 or genotype 1/2 recom-
binant viruses. Altogether, these findings confirmed the
existence of intergenotypic recombinants of B19V. Such
recombination may contribute to the genetic diversity of
B19V, while whether recombination poses a real threat
remains to be known. With regards to the other four
unclassified sequences, we assumed they were putative new
B19V genotypes or subtypes. In order to confirm their
genotypes and elucidate the biological significance of the
recombinant and unclassified strains, full-length genomic
clones should be constructed and analyzed.
There are several limitations to this study. Above all,
in view of the mere presence of B19V DNA in blood
donor samples, as low as 0.003 %, in this paper we used
the plasma pools as the samples for B19V genotyping
[56]. The plasma pools were consisted of 2000 to over
8300 donations, thus there might be several B19V strains
present in each sample, complicating data interpretation.
Here in our study, just one of these strains in each
sample was cloned and genotyped, limiting probably the
accuracy of the prevalence analysis of different B19V
genotypes. Besides, it was possible that the recombinant
sequences derived from the large plasma pool samples
were in fact amplification artefacts if B19V of multiple
origins coexisted in a sample. Secondly, the lack of full-
length sequences of B19V detected in this study, espe-
cially the recombinant and unclassified strains, was a
limitation. Finally, at present there are 29 blood product
manufacturers in China and our investigation was
restricted in three of these. Thus, the data obtained in
this study does not reflect the national circulating status
of different B19V genotypes in China. Despite these
limitations, our study represents the first report of the
cocirculation of B19V 1a, 1b and 3b in China and the
data implied the existence of putative B19V 1/3 recom-
binant and new strains.
Conclusions
In conclusion, the present data provides, for the first
time, evidence that B19V subtypes 1a, 1b and 3b are
currently circulating in Chinese plasma donors, with
genotype 1a predominating, as anticipated. Furthermore,
this is the first report of the putative B19V 1a/3b recom-
binant and unclassified strains in China as well. Such
strains may contribute to the genetic diversity of B19V
and complicate the B19V detection and consequently
have significant implications for B19V infection diagno-
sis and treatment, and for B19V NAT screening as well.
Further studies will be required to elucidate the
biological significance of the recombinant and unclassi-
fied strains.
Additional files
Additional file 1: Figure S1. Analyses of three B19V 1a/3b recombinant
sequences. The left part of each panel was the results of bootscan analysis.
At the right part of each panel were the neighbour-joining trees established
on the basis of the fragments between breakpoints, as indicated by a
bootscan plot of the sequence. (JPG 4401 kb)
Additional file 2: Table S1. Genotype of the additional clones from
samples suspected of containing recombinant B19V. (DOCX 16 kb)
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